4/12/2021 8:20:19 AM
Flagship Biosciences, Leap Therapeutics Announce Deal For Tumor Expression Assay Utilizing RNAscope And Image Analysis
3/22/2021 6:02:26 AM
Leap Therapeutics Presents DKN-01 Clinical Data At Society Of Gynecologic Oncology 2021 Meeting On Women's Cancer
3/12/2021 7:02:02 AM
Leap Therapeutics Q4 Loss Per Share $0.09 Vs Loss $0.33 Last Year
12/22/2020 10:25:10 AM
Leap Therapeutics Reports Publication Of DKN-01 Mechanism Of Action Data In Molecular Cancer Research
11/12/2020 7:36:42 AM
Leap Therapeutics Q3 Net Loss $7.1 Mln Vs. Net Loss $7.9 Mln Last Year
11/9/2020 10:00:00 AM
Leap Therapeutics Presents DKN-01 Monotherapy Data
11/9/2020 8:12:13 AM
Leap Therapeutics Presents Updated Data For DKN-01 In Esophagogastric Cancer Patients
9/24/2020 7:15:11 AM
Leap : FDA Fast Track Designation Granted To DKN-01 For Treatment Of Gastric And Gastroesophageal Junction Cancer
9/21/2020 7:06:01 AM
Leap Therapeutics And BeiGene Says First Patient Dosed In DisTinGuish Study
8/13/2020 7:08:09 AM
Leap Therapeutics Q2 Loss Per Share $0.12 Vs Loss $0.37 Last Year
6/22/2020 4:16:06 PM
Leap Therapeutics Announces Closing Of Public Offering Of Common Stock
6/18/2020 9:06:05 AM
Leap Therapeutics Announces Pricing Of $45 Mln Of Common Stock And Pre-Funded Warrants
6/17/2020 4:03:03 PM
Leap Therapeutics Announces Proposed Public Offering Of Common Stock
3/18/2020 7:02:25 AM
Leap Therapeutics Announces Executive Leadership Changes; Christopher Mirabelli To Step Down As President And CEO